FDA Inspection 599116 — Janssen Pharmaceuticals, dba Actelion Pharmaceutical

Janssen Pharmaceuticals, dba Actelion Pharmaceutical — FEI 3003498827

The FDA completed an inspection of Janssen Pharmaceuticals, dba Actelion Pharmaceutical on July 20, 2009 in South San Francisco, CA. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 2 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
July 20, 2009
Fiscal Year
2009
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
South San Francisco, CA (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
673021 CFR 314.80(b)Failure to develop written procedures
682321 CFR 314.80(c)Failure by applicant to report ADE